Watch CBS News

FDA OKs Pfizer Drug For Rare, Fast-Killing Type Of Leukemia

Follow KDKA-TV: Facebook | Twitter

TRENTON, N.J. (AP) - The Food and Drug Administration has approved a new medicine for use against a rare, rapidly progressing blood cancer after other treatments have failed.

Pfizer's Besponsa was approved for patients with a type of advanced acute lymphoblastic leukemia. By then, life expectancy is low.

Dr. Richard Pazdur, the FDA's director for cancer drugs, said the drug's approval provides a targeted option for patients with few available treatments.

This year an estimated 5,970 Americans will be diagnosed and 1,440 will die from the cancer.

The drug will cost $168,300 without insurance for a nine-week treatment course.

In testing that included 218 patients, 36 percent given Besponsa had their cancer vanish for eight months on average; 17 percent of those given chemotherapy had remission for a median five months.

(Copyright 2017 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)

View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.